Only a couple of weeks after Rubraca (rucaparib) was approved for the treatment of prostate cancer, the National Comprehensive Cancer Network (NCCN) has updated its guidelines recommending this PARP inhibitor as an option for select prostate cancer patients in the U.S. According to Clovis Oncology, which makes Rubraca, the NCCN recommends Rubraca as a “treatment option for patients with mCRPC [metastatic castration-resistant prostate cancer] and a pathogenic BRCA1 or BRCA2 mutation (…) who have been treated…
You must be logged in to read/download the full post.
The post Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients appeared first on BioNewsFeeds.